International Journal of New Findings in Health and Educational Sciences (IJHES)
ISSN 2980-0641
DOI : 10.63053/ijhes.81

Biomanufacturing for a Sustainable Future: Unleashing The Potential of Biotechnology In Pharmaceutical Raw Material Production

Marzieh Shokoohi [1]*, Tahereh Attar [2]

1. Department of Life Sciences Engineering, Faculty of New Sciences & Technologies, University of Tehran, Tehran, Iran
2. School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran

ARTICLE INFO

Keywords:
PharmaceuticalRaw Materials, Recombinant DNA Technology, Microbial Fermentation, Biocatalysis, Cell Culture Technology

ABSTRACT

The pharmaceutical industry relies heavily on raw materials for drug development, with Active Pharmaceutical Ingredients (APIs) and excipients forming the fundamental components of pharmaceutical formulations. Traditional methods of pharmaceutical raw material production are plagued by inefficiencies, environmental concerns, and limitations in producing complex molecules. In contrast, biotechnology offers a promising alternative with its capacity for efficient, sustainable, and precise synthesis of pharmaceutical raw materials. This article explores the potential of biotechnology in pharmaceutical raw material production, focusing on techniques such as recombinant DNA technology, microbial fermentation, biocatalysis, and cell culture technology. These methods enable the production of complex molecules with high specificity, purity, and scalability, addressing the shortcomings of traditional approaches. Furthermore, biotechnology facilitates the development of novel drugs, personalized medicine strategies, and innovative treatments, offering hope for previously untreatable conditions. Despite the transformative potential of biotechnology, challenges such as high initial investment, regulatory considerations, and safety concerns need to be addressed for its widespread adoption. In conclusion, embracing biotechnology represents a paradigm shift in pharmaceutical production, promising a more sustainable, personalized, and effective healthcare future. Collaboration between stakeholders is essential to navigate challenges and ensure the responsible advancement of biotechnological applications in healthcare, ultimately improving the quality of life for millions worldwide.

1. Introduction

Pharmaceutical raw materials are the cornerstone of modern medicine, providing the essential foundation for a wide range of drugs, vaccines, and treatments [1]. This includes both Active Pharmaceutical Ingredients (APIs) and excipients, which together form the basic components of pharmaceutical formulations [2]. APIs, also known as the "active ingredient" in medications, play a pivotal role in producing therapeutic effects by directly targeting specific biological processes, thereby alleviating symptoms and facilitating healing [3]. Excipients, while often perceived as inert, are equally indispensable. These inactive substances serve as vital support agents, ensuring the proper delivery, stability, and functionality of APIs within pharmaceutical formulations [4].

While traditional approaches have long served as the cornerstone of pharmaceutical raw material manufacturing, their shortcomings become increasingly apparent in light of evolving healthcare needs [5]. One of the primary limitations of conventional methods is their low efficiency, typically resulting from multi-step chemical syntheses that generate substantial waste byproducts. This not only escalates production expenses but also raises environmental concerns related to waste management. Moreover, the use of harsh chemicals and solvents in traditional processes poses a significant environmental hazard, contributing to air and water pollution, thereby impacting ecosystems and potentially endangering human health [6].

As medical science progresses, the demand for intricate and sophisticated molecules for targeted therapies surges. However, conventional methods often struggle to produce these complex structures with the required purity and efficacy [3], posing a barrier to the advancement of innovative drugs and treatments [7]. Furthermore, traditional methods heavily rely on finite natural resources, rendering them vulnerable to supply and price fluctuations. This instability can create uncertainties regarding the availability and affordability of critical pharmaceutical raw materials [8]. To meet the evolving demands of contemporary healthcare, there is an urgent need for innovative and sustainable approaches to pharmaceutical raw material production [9].

As the shortcomings of traditional methodologies become increasingly evident, the emergence of biotechnology signifies a transformative paradigm shift with the capacity to revolutionize pharmaceutical raw material production [10]. Biotechnology harnesses the inherent capabilities of living cells to synthesize desired molecules directly, often yielding higher outputs while minimizing waste. Furthermore, these methods are readily scalable to meet the escalating demand for pharmaceutical raw materials [11].

By leveraging natural processes and renewable resources, biotechnology presents a more environmentally conscious approach to manufacturing. This reduces dependence on harsh chemicals and diminishes the generation of detrimental waste byproducts [10]. The manipulation of living systems afforded by biotechnology enables the production of intricate molecules that are challenging or impossible to create through traditional means. This paves the way for the development of groundbreaking drugs and therapies targeting previously unaddressed medical conditions [12]. By harnessing biological mechanisms, biotechnology

helps alleviate the strain on finite natural resources commonly associated with traditional methodologies, thereby fostering a more robust and sustainable supply chain for pharmaceutical raw materials [13].

This article aims to explore the potential of biotechnology for manufacturing pharmaceutical raw materials. It discusses methods like recombinant DNA technology, microbial fermentation, biocatalysis, and cell culture technology used in the production of these materials.

Techniques and Applications

Recombinant DNA Technology

The advent of recombinant DNA technology has transformed pharmaceutical production by facilitating the design of customized DNA molecules. This technique involves manipulating the genetic code of organisms to generate specific proteins such as insulin, growth hormones, and antibodies on a large scale [14].

Recombinant DNA technology has significantly impacted the production of several essential proteins:

- Insulin Before the introduction of recombinant technology, individuals with diabetes relied on insulin sourced from animals, which carried the risk of allergic reactions. With recombinant DNA technology, the production of human insulin has become feasible, mitigating these risks and ensuring a consistent supply [15].
- Growth hormones: Recombinant human growth hormone is employed in treating growth deficiencies in children and hormone deficiencies in adults. By directly synthesizing the human hormone, this technology eliminates potential complications associated with animal-derived sources [16].
- Antibodies: Monoclonal antibodies play a crucial role in targeted therapies and diagnostics due to their high specificity. Recombinant DNA technology facilitates the creation of specific cell lines capable of producing these antibodies, enabling their large-scale production with consistent quality [17].

Microbial Fermentation

Microbial fermentation, an established yet innovative process, harnesses the metabolic capabilities of microorganisms such as bacteria and yeast to generate a wide array of indispensable pharmaceutical raw materials, including antibiotics, vitamins, and enzymes [18].

This adaptable technique plays a critical role in the production of various essential pharmaceutical components:

- Antibiotics: The first commercially available antibiotic, penicillin, was derived from the fungus Penicillium notatum through microbial fermentation. This groundbreaking discovery revolutionized the treatment of bacterial infections [19].

- Vitamins: Vitamin B12, essential for nervous system function, is primarily produced via microbial fermentation utilizing bacteria like Salmonella typhimurium. This method ensures a consistent and cost-effective supply of this vital nutrient [20].
- Enzymes: Numerous enzymes utilized across various industries, including pharmaceuticals, are manufactured through microbial fermentation. These enzymes serve diverse purposes, such as facilitating drug production or enabling specific biological reactions [21].
- Amino acids serve as ingredients in cosmetics, specialty nutrients, pharmaceuticals, and medical products [22]. Industrial production of amino acids employs three main biotechnological methods: enzymatic, semi-fermentation, and direct fermentation. Among these, fermentation offers economic and ecological advantages, featuring a straightforward process and utilizing renewable, cost-effective carbon sources such as sucrose, molasses, and glucose. This method also enables high production capacity for amino acids including L-Arginine, L-Glutamine, L-Histidine, L-Isoleucine, L-Leucine, L-Lysine, L-Proline, L-Serine, L-Tryptophan, L-Tyrosine, and L-Valine [23].

Biocatalysis

Biocatalysis, harnessing the catalytic power of enzymes, presents a sophisticated and efficient method for transforming raw materials into specific pharmaceutical constituents. These highly selective biological catalysts play a crucial role in enhancing the efficiency and sustainability of multiple stages within the pharmaceutical manufacturing process [24].

Illustrations of Biocatalysis in Pharmaceuticals:

- Statins: Enzymatic processes are employed in the production of statins, a class of medications utilized for reducing cholesterol levels [25].
- Antibiotics: Certain biocatalytic pathways contribute to the production and semi-synthesis of various antibiotics [26].
- Pegfilgrastim: This granulocyte colony-stimulating factor, utilized to boost white blood cell counts following chemotherapy, is synthesized using biocatalysis [27].

Cell Culture Technology

Cell culture technology, a pivotal component of contemporary biotechnology, entails the cultivation of animal or plant cells within a regulated environment to generate diverse complex molecules with medical significance. This technique assumes a critical role in both the advancement and manufacture of life-saving products such as vaccines and monoclonal antibodies [28].

Applications in Pharmaceuticals:

- Vaccines: Cell culture technology serves as the cornerstone of modern vaccine production. Live-attenuated, inactivated, or subunit vaccines can all be manufactured

utilizing cultured cells, providing a safe and efficacious means of disease prevention [29].

- Monoclonal Antibodies: These highly precise molecules, utilized for targeted therapy and diagnostic purposes, are synthesized through genetically engineered cells cultured under controlled conditions [30].
- Gene Therapy: Cell culture technology plays a vital role in the development and production of cell-based therapies, where genetically modified cells are employed for treating various medical conditions [31].

Advantages of Using Biotechnology

Increased efficiency and production

Biotechnology has transformed the landscape of pharmaceutical raw material production through its capacity for large-scale and efficient synthesis of specific molecules [32].

Biotechnology frequently yields higher quantities of the desired product, thereby lowering production expenses and minimizing waste [33]. Bioprocesses can be readily scaled up or down to accommodate production requirements, offering both flexibility and cost-effectiveness [34].

Specificity and purity

Biotechnology stands out in the creation of exceptionally specific and pure pharmaceutical raw materials [35].

Methods such as recombinant DNA technology facilitate the synthesis of precise protein variants with targeted therapeutic properties. This capability fosters the development of personalized medicine strategies [36]. Traditional preparations often contain impurities that contribute to adverse reactions. Through the production of highly pure materials, biotechnology diminishes the likelihood of side effects and enhances the overall safety profile of drugs [37]. Bioprocesses provide enhanced control over production parameters, resulting in consistent product quality and improved medication efficacy [38].

Reduced dependence on natural sources

Biotechnology presents a robust solution to address challenges associated with sourcing raw materials from natural reservoirs [10].

For rare or endangered species, traditional methods often involve extracting materials from plants or animals facing extinction, raising ethical and sustainability concerns. Biotechnology offers an alternative approach by generating identical molecules in controlled environments [39]. Moreover, certain natural resources suffer from limited availability due to geographic constraints. Bioprocesses offer a solution by producing desired molecules independently of such limitations [40]. Furthermore, natural sources frequently exhibit variations in quality and potency, leading to inconsistencies in drug production. Biotechnology ensures consistent quality and purity of raw materials [35].

Illustratively, the production of the antimalarial drug Artemisinin traditionally relied on scarce Artemisia annua plants. However, biotechnology now facilitates its production using genetically engineered yeast, ensuring a dependable and sustainable supply for this crucial medication [41].

Similarly, the development of synthetic spider silk, renowned for its exceptional strength and elasticity, faces ethical challenges in large-scale harvesting from spiders. Biotechnology provides a viable solution by producing spider silk proteins in genetically modified organisms [42].

Development of novel drugs

Biotechnology has emerged as an indispensable instrument in the exploration and advancement of innovative drugs [43].

Identification of New Drug Targets: Cutting-edge methodologies such as gene sequencing and protein analysis enable the discovery of novel targets for drug development, paving the way for the creation of entirely new classes of medications [44]. High-throughput Drug Screening: Through the utilization of automated systems and genetically modified cells, biotechnology facilitates the rapid screening of extensive libraries of potential drug candidates, expediting the discovery process [45]. Development of Gene Therapies: By directly targeting the genetic origins of diseases, biotechnology facilitates the development of potentially curative gene therapies for previously untreatable conditions [46].

Remarkable Examples of Novel Drugs Developed Through Biotechnology:

- Immunotherapy Drugs: These medications harness the body's immune system to combat cancer, presenting a groundbreaking approach to cancer treatment [47].
- Genetically Engineered Enzymes: These enzymes can substitute defective ones in patients afflicted with genetic disorders, offering a potential cure for previously incapacitating diseases such as cystic fibrosis [48].

Disadvantages and Challenges

High initial investment

Although the potential of bio-manufacturing for producing pharmaceutical raw materials is undeniable, a substantial barrier to entry exists in the form of high initial investment [49]. Establishing and maintaining bio-manufacturing facilities necessitates specialized equipment, controlled environments, and highly skilled personnel [50].

Consequently, this results in significant upfront costs, encompassing:

- Facility construction and infrastructure: Erecting a bio-manufacturing facility that complies with stringent regulatory standards and upholds sterile conditions can incur substantial expenses [51].

- Equipment and technology: Bio-manufacturing processes frequently require specialized equipment such as fermentation apparatus, bioreactors, purification systems, and quality control instruments [52].
- Research and development: The development and optimization of bio-manufacturing processes tailored for specific pharmaceutical raw materials often demand extensive research and development endeavors, further augmenting the initial investment [53].

Regulatory considerations

Biotechnologically derived drugs, including those produced through bio-manufacturing, are subject to stringent regulations and lengthy approval processes compared to traditionally manufactured pharmaceuticals [54].

The complexity and novelty inherent in biologics, unlike traditional pharmaceuticals, often involve molecules produced by living organisms, necessitating comprehensive evaluation of their safety and efficacy [55]. Regulatory bodies face the task of ensuring the safety of both the production process and the final product, which may entail addressing concerns related to genetically modified organisms and biohazards [56]. Moreover, as biotechnology progresses rapidly, regulatory frameworks must evolve to address emerging challenges and uphold ongoing safety standards [57].

Safety concerns

Bio-manufacturing entails working with living organisms, including genetically modified ones, as well as potentially hazardous materials, raising concerns regarding the safety of both workers and the environment [58].

The accidental release of genetically modified organisms presents a significant risk, potentially leading to unintended ecological consequences and disruptions to natural ecosystems [59]. Moreover, bio-manufacturing processes involve the handling of pathogens or hazardous materials, posing risks of infection or exposure for workers [60]. Additionally, the generation of waste streams during bio-manufacturing necessitates specialized treatment and disposal methods to minimize environmental impact [61].

Future Directions and Conclusion

Gene Editing

Gene editing technologies, particularly the revolutionary CRISPR-Cas system, are reshaping the landscape of pharmaceutical raw material production. CRISPR-Cas enables scientists to precisely modify an organism's DNA with unparalleled accuracy and efficiency [62].

Developing personalized medicine: By editing the genes associated with specific diseases such as cystic fibrosis or sickle cell anemia, researchers can explore gene therapy avenues, addressing these conditions at their genetic root [63, 64]. Creating disease models in cell lines and organisms: Introducing specific mutations linked to diseases into cell lines or model

organisms enables scientists to investigate disease mechanisms and test potential treatments in controlled environments [65]. Engineering organisms for enhanced pharmaceutical production: Gene editing facilitates the enhancement of specific metabolites or proteins in organisms, leading to a more efficient and sustainable production of valuable pharmaceutical components [66].

Synthetic Biology

Synthetic biology empowers scientists to conceive and construct novel biological systems tailored to specific functionalities [67].

Engineering organisms for customized drug production: Researchers can manipulate bacteria, yeast, or other organisms to efficiently and precisely produce particular drugs or their precursors [68]. Designing advanced drug delivery systems: Synthetic biology enables the development of targeted drug delivery systems capable of releasing medications at predetermined locations within the body, thereby minimizing side effects and enhancing efficacy [69]. Creating biosensors for disease diagnosis and monitoring: Synthetic biology offers the opportunity to design biosensors capable of detecting specific biomarkers associated with diseases, facilitating early diagnosis and personalized treatment approaches [70].

Personalized Medicine

Personalized medicine endeavors to customize medical treatments and therapies according to the unique genetic composition of each individual [71].

Developing drugs tailored to individual genetic profiles: Through the analysis of a patient's specific genes, physicians can prescribe medications that are most likely to be effective and have minimal side effects [72]. Optimizing treatment dosage and duration: Personalized medicine enables the adjustment of treatment dosage and duration based on a patient's individual response and genetic variations, maximizing therapeutic benefits while minimizing potential risks [73]. Designing preventive strategies based on genetic risk factors: Identification of genetic predispositions to certain diseases facilitates the implementation of preventative measures and early interventions, potentially even before symptoms manifest [74].

Conclusion

Embracing Biotechnology for a Sustainable Pharmaceutical Future

In conclusion, the growing importance of biotechnology in the production of pharmaceutical raw materials heralds a new era of innovation and sustainability in healthcare. Traditional methods, while foundational, are increasingly constrained by their limitations in efficiency, environmental impact, and adaptability to evolving healthcare needs. Biotechnology, with its ability to harness the power of living organisms and genetic manipulation, offers a transformative solution to these challenges.

Through techniques like recombinant DNA technology, microbial fermentation, biocatalysis,

and cell culture technology, biotechnology enables the efficient and scalable production of pharmaceutical raw materials with unprecedented precision and purity. By reducing reliance on limited natural resources and offering alternatives to environmentally damaging processes, biotechnology paves the way for a more sustainable pharmaceutical industry.

Moreover, biotechnology fuels the discovery and development of novel drugs, from immunotherapy for cancer to gene therapies for genetic disorders, offering hope for previously untreatable conditions. With advancements in gene editing, synthetic biology, and personalized medicine, the potential for tailored treatments based on individual genetic profiles becomes increasingly feasible, promising more effective and personalized healthcare solutions.

However, challenges such as high initial investment, regulatory considerations, and safety concerns must be addressed to fully realize the potential of biotechnology in pharmaceutical production. Collaboration between researchers, industry stakeholders, and regulatory bodies is crucial to navigate these challenges and ensure the safe and responsible advancement of biotechnological applications in healthcare.

In essence, embracing biotechnology represents not only a paradigm shift in pharmaceutical production but also a commitment to a more sustainable, personalized, and effective healthcare future. By leveraging the power of living systems and genetic manipulation, we can revolutionize drug discovery, production, and delivery, ultimately improving the quality of life for millions around the globe. As we stand on the cusp of a biotechnological revolution, the integration of biotechnology into pharmaceutical production stands as a testament to human ingenuity and our collective commitment to advancing the frontiers of healthcare.

References

1. Kh, Ulaan-Od, and Baoyintu Bai. "The study regarding pharmaceutical raw material of animal derived medicine in “Ocean of medicine names”." *Mongolian Medical Sciences* (2022): 33-37.
2. Bharate, Sonali S., Sandip B. Bharate, and Amrita N. Bajaj. "Interactions and incompatibilities of pharmaceutical excipients with active pharmaceutical ingredients: a comprehensive review." *Journal of Excipients and Food Chemicals* 1.3 (2016).
3. Lu, Jie, and Sohrab Rohani. "Polymorphism and crystallization of active pharmaceutical ingredients (APIs)." *Current Medicinal Chemistry* 16.7 (2009): 884-905.
4. Chaudhari, Shilpa P., and Pradeep S. Patil. "Pharmaceutical excipients: a review." *Int J Adv Pharm Biol Chem* 1.1 (2012): 21-34.
5. Phillips, Daniel J., et al. "Overcoming sink limitations in dissolution testing: a review of traditional methods and the potential utility of biphasic systems." *Journal of Pharmacy and Pharmacology* 64.11 (2012): 1549-1559.
6. Castiello, Carola, et al. "GreenMedChem: the challenge in the next decade toward eco-friendly compounds and processes in drug design." *Green Chemistry* 25.6 (2023): 2109-2169.
7. Sethi, Nilay, and Yibin Kang. "Unravelling the complexity of metastasis—molecular understanding and targeted therapies." *Nature Reviews Cancer* 11.10 (2011): 735-748.
8. Gurnani, N., et al. "Natural products: source of potential drugs." *Afr J Basic Appl Sci* 6.6 (2014): 171-186.
9. Salgueiro, L., A. P. Martins, and H. Correia. "Raw materials: the importance of quality and safety. A review." *Flavour and Fragrance Journal* 25.5 (2010): 253-271.

10. Gavrilescu, Maria, and Yusuf Chisti. "Biotechnology—a sustainable alternative for chemical industry." *Biotechnology advances* 23.7-8 (2005): 471-499.
11. Walsh, Gary. "Pharmaceutical biotechnology: concepts and applications." (2007).
12. Schulman, Kevin A., K. Robin Yabroff, and Henry Glick. "A health services approach for the evaluation of innovative pharmaceutical and biotechnology products." *Drug information journal* 29.4 (1995): 1405-1414.
13. Kumara Behera, Basanta, et al. "Microbial Products Supply Chain." *Microbial Biomass Process Technologies and Management* (2017): 215-255.
14. Khan, Suliman, et al. "Role of recombinant DNA technology to improve life." *International journal of genomics* 2016 (2016).
15. Johnson, Irving S. "Human insulin from recombinant DNA technology." *Science* 219.4585 (1983): 632-637.
16. Salomon, Franco, et al. "The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency." *New England Journal of Medicine* 321.26 (1989): 1797-1803.
17. Rowell, Frederick J., and JAMES R. FURR. "Recombinant DNA technology: monoclonal antibodies." *Smith and Williams' Introduction to the Principles of Drug Design and Action*. CRC Press, 2019. 491-508.
18. Hill, Daragh, et al. "Recent advances in microbial fermentation for dairy and health." *F1000Research* 6 (2017).
19. Hook, Derek J. "Production of antibiotics by fermentation." *Basic Biotechnology* (2006): 433.
20. Survase, Shrikant A., Ishwar B. Bajaj, and Rekha S. Singhal. "Biotechnological Production of Vitamins." *Food Technology & Biotechnology* 44.3 (2006).
21. Vittaladevaram, Viswanath. "Fermentative Production of Microbial Enzymes and their Applications: Present status and future prospects." *Journal of Applied Biology and Biotechnology* 5.4 (2017): 090-094.
22. D'Este, Martina, Merlin Alvarado-Morales, and Irini Angelidaki. "Amino acids production focusing on fermentation technologies–A review." *Biotechnology advances* 36.1 (2018): 14-25.
23. Ivanov, Kalin, et al. "Biotechnology in the production of pharmaceutical industry ingredients: amino acids." *Biotechnology & Biotechnological Equipment* 27.2 (2013): 3620-3626.
24. Bell, Elizabeth L., et al. "Biocatalysis." *Nature Reviews Methods Primers* 1.1 (2021): 46.
25. Hoyos, Pilar, Vittorio Pace, and Andrés R. Alcántara. "Biocatalyzed synthesis of statins: A sustainable strategy for the preparation of valuable drugs." *Catalysts* 9.3 (2019): 260.
26. Wegman, Margreth A., et al. "Towards biocatalytic synthesis of β-lactam antibiotics." *Advanced Synthesis & Catalysis* 343.6-7 (2001): 559-576.
27. Veronese, Francesco M., and Anna Mero. "The impact of PEGylation on biological therapies." *BioDrugs* 22 (2008): 315-329.
28. Ozturk, Sadettin, and Wei-Shou Hu, eds. *Cell culture technology for pharmaceutical and cell-based therapies*. CRC press, 2005.
29. Rappuoli, Rino. "Cell-culture-based vaccine production: technological options." *BRIDGE-WASHINGTON-NATIONAL ACADEMY OF ENGINEERING*- 36.3 (2006): 25.
30. Li, Feng, et al. "Cell culture processes for monoclonal antibody production." *MAbs*. Vol. 2. No. 5. Taylor & Francis, 2010.
31. Caplan, Arnold I. "Mesenchymal stem cells and gene therapy." *Clinical Orthopaedics and Related Research (1976-2007)* 379 (2000): S67-S70.
32. Soetaert, Wim, and Erick Vandamme. "The impact of industrial biotechnology." *Biotechnology Journal: Healthcare Nutrition Technology* 1.7-8 (2006): 756-769.
33. Wohlgemuth, Roland. "The locks and keys to industrial biotechnology." *New Biotechnology* 25.4 (2009): 204-213.
34. Demling, Philipp, et al. "Quantitative measurements in single-cell analysis: towards scalability in microbial bioprocess development." *Current opinion in biotechnology* 54 (2018): 121-127.
35. Conner, John, et al. "The biomanufacturing of biotechnology products." *Biotechnology entrepreneurship*. Academic Press, 2014. 351-385.

36. Aggarwal, Saurabh. "Targeted cancer therapies." *Nature reviews. Drug discovery* 9.6 (2010): 427.
37. Tang, Lisa, et al. "Pharmacokinetic aspects of biotechnology products." *Journal of pharmaceutical sciences* 93.9 (2004): 2184-2204.
38. Neubauer, Peter, et al. "Consistent development of bioprocesses from microliter cultures to the industrial scale." *Engineering in Life Sciences* 13.3 (2013): 224-238.
39. Tibbetts, John H. "Synthetic Biology and Endangered Species: Should scientists genetically rewire nature to save species and habitats?." *BioScience* 72.7 (2022): 610-617.
40. Manole-Paunescu, Anca. "Biotechnology for endangered plant conservation." *Biotechnology and Biodiversity* (2014): 181-202.
41. Liu, Chunzhao, Yan Zhao, and Yuchun Wang. "Artemisinin: current state and perspectives for biotechnological production of an antimalarial drug." *Applied microbiology and biotechnology* 72 (2006): 11-20.
42. Vendrely, Charlotte, and Thomas Scheibel. "Biotechnological production of spider-silk proteins enables new applications." *Macromolecular bioscience* 7.4 (2007): 401-409.
43. Duelen, Robin, et al. "Medicinal biotechnology for disease modeling, clinical therapy, and drug discovery and development." *Introduction to Biotech Entrepreneurship: From Idea to Business: A European Perspective* (2019): 89-128.
44. Salfeld, Jochen G. "Use of new biotechnology to design rational drugs against newly defined targets." *Best Practice & Research Clinical Rheumatology* 18.1 (2004): 81-95.
45. Zeng, Weizhu, et al. "High-throughput screening technology in industrial biotechnology." *Trends in biotechnology* 38.8 (2020): 888-906.
46. Ma, Cui-Cui, et al. "The approved gene therapy drugs worldwide: from 1998 to 2019." *Biotechnology advances* 40 (2020): 107502.
47. Riley, Rachel S., et al. "Delivery technologies for cancer immunotherapy." *Nature reviews Drug discovery* 18.3 (2019): 175-196.
48. Fasim, Aneesa, Veena S. More, and Sunil S. More. "Large-scale production of enzymes for biotechnology uses." *Current opinion in biotechnology* 69 (2021): 68-76.
49. Rathore, Anurag S., Deepak Kumar, and Nikhil Kateja. "Role of raw materials in biopharmaceutical manufacturing: risk analysis and fingerprinting." *Current opinion in biotechnology* 53 (2018): 99-105.
50. Broeze, Robert J. "Key challenges facing bio manufacturing." *Bioprocessing and Biopartnering* 2006 (2006): 14-16.
51. Kitney, Richard I. "Building the UK's industrial base in engineering biology." *Engineering Biology* 5.4 (2021): 98-106.
52. Gargalo, Carina L., et al. "Towards smart biomanufacturing: a perspective on recent developments in industrial measurement and monitoring technologies for bio-based production processes." *Journal of Industrial Microbiology & Biotechnology: Official Journal of the Society for Industrial Microbiology and Biotechnology* 47.11 (2020): 947-964.
53. Gargalo, Carina L., et al. "Towards the development of digital twins for the bio-manufacturing industry." *Digital twins: Tools and concepts for smart biomanufacturing* (2021): 1-34.
54. Miller, John. "Beyond biotechnology: FDA regulation of nanomedicine." *Colum. Sci. & Tech. L. Rev.* 4 (2002): 1.
55. Brennan, Frank R., et al. "Current strategies in the non-clinical safety assessment of biologics: New targets, new molecules, new challenges." *Regulatory Toxicology and Pharmacology* 98 (2018): 98-107.
56. Chen, Chao, and Genserik Reniers. "Risk assessment of processes and products in industrial biotechnology." *Sustainability and Life Cycle Assessment in Industrial Biotechnology* (2020): 255-279.
57. Pimenta, Cleila, et al. "Advanced therapies and regulatory framework in different areas of the globe: past, present, and future." *Clinical Therapeutics* 43.5 (2021): e103-e138.
58. Li, Jing, et al. "Advances in synthetic biology and biosafety governance." *Frontiers in bioengineering and biotechnology* 9 (2021): 598087.
59. Cardwell, Michael. "The Release of Genetically Modified Organisms into the Environment: Public Concerns and Regulatory Responses." *Environmental Law Review* 4.3 (2002): 156-170.

60. Murashov, Vladimir, John Howard, and Paul Schulte. "Synthetic Biology Industry: Biosafety Risks to Workers." *Synthetic Biology 2020: Frontiers in Risk Analysis and Governance* (2020): 165-182.
61. Udugama, Isuru A., et al. "Perspectives on resource recovery from bio-based production processes: from concept to implementation." *Processes* 5.3 (2017): 48.
62. Hashemi, Atieh. "CRISPR-Cas system as a genome engineering platform: applications in biomedicine and biotechnology." *Current Gene Therapy* 18.2 (2018): 115-124.
63. Hong, Andrew. "CRISPR in personalized medicine: Industry perspectives in gene editing." *Seminars in perinatology*. Vol. 42. No. 8. WB Saunders, 2018.
64. Germino-Watnick, Paula, et al. "Hematopoietic stem cell gene-addition/editing therapy in sickle cell disease." *Cells* 11.11 (2022): 1843.
65. Zarei, Ali, et al. "Creating cell and animal models of human disease by genome editing using CRISPR/Cas9." *The journal of gene medicine* 21.4 (2019): e3082.
66. Collins, Joseph H., and Eric M. Young. "Genetic engineering of host organisms for pharmaceutical synthesis." *Current opinion in biotechnology* 53 (2018): 191-200.
67. Andrianantoandro, Ernesto, et al. "Synthetic biology: new engineering rules for an emerging discipline." *Molecular systems biology* 2.1 (2006): 2006-0028.
68. David, Florian, et al. "A perspective on synthetic biology in drug discovery and development—current impact and future opportunities." *SLAS DISCOVERY: Advancing the Science of Drug Discovery* 26.5 (2021): 581-603.
69. Li, Yujie, et al. "Advances in synthetic biology-based drug delivery systems for disease treatment." *Chinese Chemical Letters* (2024): 109576.
70. Wang, Chi, et al. "Biosensor-based therapy powered by synthetic biology." *Smart Materials in Medicine* 4 (2023): 212-224.
71. Goetz, Laura H., and Nicholas J. Schork. "Personalized medicine: motivation, challenges, and progress." *Fertility and sterility* 109.6 (2018): 952-963.
72. Nair, Sunita R. "Personalized medicine: Striding from genes to medicines." *Perspectives in clinical research* 1.4 (2010): 146.
73. Ong, Frank S., et al. "Personalized medicine in ophthalmology: from pharmacogenetic biomarkers to therapeutic and dosage optimization." *Journal of personalized medicine* 3.1 (2013): 40-69.
74. Salari, Keyan, Hugh Watkins, and Euan A. Ashley. "Personalized medicine: hope or hype?." *European heart journal* 33.13 (2012): 1564-1570.